23 completed, 6 terminated, 2 unknown, 1 not yet recruiting. 33 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 33 | Completed 23, Terminated 6, Unknown 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Acromegaly: new trials by email Literature Review of Acromegaly trials Research Report on Acromegaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT) - Acromegaly Due to Pituitary Adenoma, Cushing's Disease | Phase 3 | Not yet recruiting | University College, London | 82 | 2026-09-01 | 2026-10-01 |
| A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs Debio 4126, Placebo - Acromegaly | Phase 3 | Recruiting | Debiopharm International SA | 119 | 2025-11-26 | 2026-10-23 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) Paltusotine, Placebo - Acromegaly | Phase 3 | Terminated | Crinetics Pharmaceuticals Inc. | 111 | 2021-12-17 | 2026-07-15 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly Paltusotine, Placebo - Acromegaly | Phase 3 | Terminated | Crinetics Pharmaceuticals Inc. | 58 | 2021-05-12 | 2026-07-15 |
| A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly CAM2029 (octreotide subcutaneous depot) - Acromegaly | Phase 3 | Completed | Camurus AB | 135 | 2019-10-10 | 2025-12-22 |
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly CAM2029 (octreotide subcutaneous depot), Matching placebo - Acromegaly | Phase 3 | Completed | Camurus AB | 72 | 2019-08-19 | 2026-08-20 |
| Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection - Acromegaly Due to Pituitary Adenoma | Phase 3 | Unknown | Samsung Medical Center | 90 | 2018-03-01 | 2018-03-01 |
| Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly octreotide capsules, Matching placebo - Acromegaly | Phase 3 | Unknown | Chiasma, Inc. | 56 | 2017-09-01 | 2020-11-23 |
| Strict IGF-1 Control in Acromegaly Pegvisomant - Acromegaly | Phase 3 | Completed | Unity Health Toronto | 10 | 2017-07-27 | 2021-11-22 |
| Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly Octreotide capsules - Acromegaly | Phase 3 | Completed | Chiasma, Inc. | 146 | 2016-02-01 | 2022-04-22 |
| Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Pasireotide LAR - Acromegaly | Phase 3 | Completed | Novartis Pharmaceuticals | 123 | 2015-03-31 | 2019-12-10 |
| Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Gallium-68 DOTATOC PET - Pituitary Tumours | Phase 3 | Terminated | Göteborg University | 22 | 2015-01-01 | 2022-03-31 |
| Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Lanreotide Autogel®, Lanreotide Acetate - Acromegaly | Phase 3 | Completed | Ipsen | 128 | 2014-10-01 | 2019-01-29 |
| Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Octreotide capsules - Acromegaly | Phase 3 | Completed | Chiasma, Inc. | 155 | 2012-03-01 | 2017-08-17 |
| Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly Octreotide - Acromegaly | Phase 3 | Terminated | Endo USA Inc., a Keenova Therapeutics Company | 12 | 2011-02-01 | 2013-09-20 |
| Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg - Acromegaly | Phase 3 | Completed | Novartis Pharmaceuticals | 198 | 2010-07-19 | 2018-04-05 |
| Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly Octreotide Implant, Sandostatin LAR Depot - Acromegaly | Phase 3 | Terminated | Endo USA Inc., a Keenova Therapeutics Company | 169 | 2008-09-01 | 2013-09-27 |
| Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Lanreotide autogel 120 mg - Acromegaly | Phase 3 | Completed | Ipsen | 108 | 2008-05-01 | 2022-10-14 |
| Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Pasireotide, Octreotide - Acromegaly | Phase 3 | Completed | Novartis Pharmaceuticals | 358 | 2008-02-11 | 2017-07-02 |
| Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients C2L-OCT-01 PR, 10 or 20 mg, C2L-OCT-01 PR, 20 mg - Acromegaly | Phase 3 | Terminated | Ambrilia Biopharma, Inc. | 40 | 2008-02-01 | 2010-02-09 |
Showing 20 of 33. Sign in to see all of them.
Pituitary Neoplasms (5) · Pituitary Diseases (3) · Adenoma (2) · Gigantism (2) · Growth Hormone-Secreting Pituitary Adenoma (2) · Fibrous Dysplasia, Polyostotic (1) · Growth Disorders (1) · Hyperplasia (1) · Pituitary ACTH Hypersecretion (1)
Bone Diseases (33) · Bone Diseases, Endocrine (33) · Brain Diseases (33) · Central Nervous System Diseases (33) · Endocrine System Diseases (33) · Hyperpituitarism (33) · Hypothalamic Diseases (33) · Musculoskeletal Diseases (33) · Nervous System Diseases (33) · Pituitary Diseases (30) · Neoplasms (6) · Brain Neoplasms (5) · Central Nervous System Neoplasms (5) · Endocrine Gland Neoplasms (5) · Hypothalamic Neoplasms (5)
Octreotide (8) · lanreotide (8) · pegvisomant (4) · pasireotide (3) · Duration of Therapy (2) · Injections (1) · Proton Therapy (1) · Radiosurgery (1) · Radiotherapy, Intensity-Modulated (1) · Solutions (1) · Suspensions (1)
Ipsen (8) · Novartis Pharmaceuticals (5) · Ambrilia Biopharma, Inc. (3) · Chiasma, Inc. (3) · Camurus AB (2) · Crinetics Pharmaceuticals Inc. (2) · Endo USA Inc., a Keenova Therapeutics Company (2) · Debiopharm International SA (1) · Göteborg University (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · Novartis (1) · Pfizer (1) · Samsung Medical Center (1) · Unity Health Toronto (1) · University College, London (1)
United States (16) · Hungary (15) · Italy (15) · Germany (14) · United Kingdom (14) · France (11) · Poland (11) · Serbia (9) · Spain (9) · Romania (8) · Russia (7) · Turkey (Türkiye) (7) · Belgium (6) · Brazil (6) · Israel (6)
Raphael Naudin, M.D. (3) · Constance Chik, MD (1) · Diego Ferone, M.D (1) · Maria Fleseriu, M.D., FACE (1) · Michael Kosmin (1) · Pamela Freda, M.D (1) · Shlomo Melmed, MD (1) · Stephan Petersenn, MD (1) · Susan L Samson, MD PhD (1)
PMID 34173129, PMID 40418492, PMID 18248639, PMID 19542735, PMID 19639415, PMID 19898989, PMID 21086246, PMID 21148630, PMID 21212103, PMID 23969184, PMID 24423301, PMID 25103549, PMID 25260838, PMID 25664604, PMID 26437217, PMID 26603536, PMID 27039081, PMID 32117045, PMID 32217809, PMID 32366244, PMID 32882036, PMID 34953531, PMID 39378125
2019 (2), 2004 (1), 2014 (1), 2015 (1)